MARKET

SLDB

SLDB

SOLID BIOSCIENCE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.41
+0.01
+0.05%
Opening 11:31 03/08 EST
OPEN
9.10
PREV CLOSE
9.40
HIGH
9.91
LOW
9.07
VOLUME
398.84K
TURNOVER
--
52 WEEK HIGH
11.58
52 WEEK LOW
1.930
MARKET CAP
568.53M
P/E (TTM)
-4.5795
1D
5D
1M
3M
1Y
5Y
BRIEF-Solid Biosciences Announces Appointments To Management Team And Board Of Directors
reuters.com · 4d ago
Solid Biosciences Reports Inducement Grant to New Chief Legal Officer
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to it...
GlobeNewswire · 4d ago
Solid Biosciences Names Clare Kahn, Georgia Keresty to Board
Solid Biosciences Names Clare Kahn, Georgia Keresty to Board
Dow Jones · 4d ago
Solid Biosciences Says Erin Powers Brennan Has Joined the Co as Chief Legal Officer >SLDB
Solid Biosciences Says Erin Powers Brennan Has Joined the Co as Chief Legal Officer >SLDB
Dow Jones · 4d ago
Solid Biosciences Announces Appointments to Management Team and Bd of Directors >SLDB
Solid Biosciences Announces Appointments to Management Team and Bd of Directors >SLDB
Dow Jones · 4d ago
Solid Biosciences Says Joel Schneider Promoted to Chief Operating Officer >SLDB
Solid Biosciences Says Joel Schneider Promoted to Chief Operating Officer >SLDB
Dow Jones · 4d ago
Solid Biosciences Announces Appointments to Management Team and Board of Directors
-Adding senior level experience to help advance programs for Duchenne muscular dystrophy- CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duch...
GlobeNewswire · 4d ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 02/25 13:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLDB. Analyze the recent business situations of SOLID BIOSCIENCE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLDB stock price target is 6.70 with a high estimate of 12.50 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 57.80M
% Owned: 95.62%
Shares Outstanding: 60.45M
TypeInstitutionsShares
Increased
33
18.03M
New
36
11.19M
Decreased
11
427.90K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.93%
Pharmaceuticals & Medical Research
+1.17%
Key Executives
Chairman/Director
Ian Smith
President/Chief Executive Officer/Co-Founder/Director
Ilan Ganot
Chief Financial Officer
Stephen DiPalma
Chief Operating Officer
Joel Schneider
Chief Scientific Officer
Carl Morris
Other
Erin Brennan
Secretary
Lynette Herscha
Director
Clare Kahn
Director
Georgia Keresty
Independent Director
Matthew Arnold
Independent Director
Martin Freed
Independent Director
Robert Huffines
Independent Director
Adam Koppel
Independent Director
Sukumar Nagendran
Independent Director
Rajeev Shah
Independent Director
Adam Stone
Independent Director
Lynne Sullivan
No Data
About SLDB
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

Webull offers kinds of Solid Biosciences Inc stock information, including NASDAQ:SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.